Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Decipher LabsBOM:524752 -4.70%57 Interest Coverage is No Debt (1) as of Mar. 2026, which is 100% below its 10-year median of 51.96. GuruFocus rates BOM:524752 with a GF Score™ of 57/100 and a GF Value™ of ₹6.34 (Fairly Valued). The stock has 3 warning signs investors should review. Among 687 Drug Manufacturers companies, Decipher Labs ranks better than 99.71% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Decipher Labs's
Operating Income
for the
three
months ended in Mar. 2026 was ₹0.8 Mil. Decipher Labs's Interest Expense for the
three
months ended in Mar. 2026 was ₹0.0 Mil.
Decipher Labs has no debt.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Decipher Labs Ltd has enough cash to cover all of its debt. Its financial situation is stable.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Decipher Labs's Interest Coverage or its related term are showing as below:
BOM:524752'
s Interest Coverage Range Over the Past 10 Years
Min: 2.75 Med: 51.96 Max: No Debt
Current: No Debt
BOM:524752's Interest Coverage is ranked better than 99.71% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs BOM:524752: No Debt
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Decipher Labs Interest Coverage Related Terms
Decipher Labs Interest Coverage Historical Data
* Premium members only.
The historical data trend for Decipher Labs's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:524752 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Decipher Labs's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Decipher Labs Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Decipher Labs's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Decipher Labs's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Decipher Labs (BOM:524752) has a Interest Coverage of No Debt (1) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Decipher Labs and its competitors. This is 98% below median its historical median of 51.96. Over the past decade, Decipher Labs' Interest Coverage has ranged from 2.75 to 10,000.00. According to the industry distribution chart, Decipher Labs ranks #2 out of 687 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is Decipher Labs' Interest Coverage too high?
Decipher Labs' current Interest Coverage of No Debt (1) is 98% below median its 10-year median of 51.96. Over the past 10 years, this metric has ranged from a low of 2.75 to a high of 10,000.00. Based on the distribution chart, Decipher Labs ranks #2 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Decipher Labs has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Decipher Labs' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Decipher Labs ranks #2 out of 687 companies for Interest Coverage. This places Decipher Labs in the top 0% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.75. Historically, Decipher Labs' own Interest Coverage has ranged from 2.75 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Decipher Labs and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Decipher Labs's current Interest Coverage is No Debt (1), which is 98% below median its own 10-year median of 51.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decipher Labs stock overvalued right now?
Based on GuruFocus' analysis, Decipher Labs (BOM:524752) is currently considered Fairly Valued. The stock's GF Value™ is ₹6.34, compared to a current price of ₹6.29 — trading 0.8% below its estimated fair value. The current Interest Coverage is No Debt (1), which is 98% below median its 10-year median of 51.96. Decipher Labs' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Decipher Labs (BOM:524752), the current Interest Coverage is No Debt (1) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Decipher Labs (BOM:524752) Overvalued in 2026?
Based on GuruFocus' analysis, Decipher Labs stock appears to be undervalued.
The current stock price of ₹6.29 is trading 0.8% below its estimated GF Value™ of ₹6.34.
GuruFocus considers Decipher Labs to be Fairly Valued.
Key valuation signals for BOM:524752:
Interest Coverage: No Debt (1) (98% below median its 10-year median of 51.96)
GF Value™: ₹6.34 vs. price of ₹6.29 (0.8% below fair value)
No single metric tells the full story. See the BOM:524752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Decipher Labs Ltd deals in the trading and manufacturing of Pharmaceutical drugs and allied products and services, and also offers services and key solutions in the Information Technology industry. It is involved in the manufacturing and marketing of its branded pharmaceutical products, and also provides drug development and manufacturing services to various formulators, manufacturers, and Research and Development agencies for their bulk needs. The group's IT Consultancy offerings include Technology Integration and Systems Consulting, Software Development Consulting, and Management of IT projects. Its reportable operating segments are: Pharmaceutical, which generates the maximum revenue, and IT Consultancy Services. Geographically, the group derives its key revenue from India.
57GF Score
Get the complete analysis for BOM:524752
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524752 has been successfully added to your 
